1. Catalog
  2. Management of Portal Hypertension in Patients with ...
Management of Portal Hypertension in Patients with HCC
Create Account
Availability
Registration Required
Online Meeting
Jul 28, 2026 12:00 PM - 1:00 PM ET
Cost
$0.00
Credit Offered
No Credit Offered
  • Description
  • Learning Objectives
  • Faculty and Disclosures
  • Recommended
Management of Portal Hypertension in patients with HCC is very challenging. There are several areas that remain controversial including bleeding risk from gastroesophageal varices in the setting of systemic therapy with Anti-VEGF based combinations for HCC. The optimal management strategy in such patients requires a multidisciplinary approach. Additionally, among patients with HCC presenting with variceal bleeding, the role of TPC to manage variceal bleeding event and prevent future bleeding during the HCC treatment is unclear. Careful selection of potential candidates is key in these complicated situations. This webinar is intended to provide a framework and answer commonly encountered questions in the scenarios based on available evidence. This webinar is intended for gastroenterologists, hepatologists, fellows, trainees and nurse practitioners. Others with an interest in management of portal hypertension are invited to attend.
Upon completion of this activity, participants should be able to:
• Identify the optimal management strategy for prevention of variceal bleeding in patients with HCC
• Identify the optimal treatment for acute variceal bleeding in high-risk patients with HCC, with special attention to TPC candidacy

This educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence in Accredited Continuing Education by members of the Continuing Medical Education Committee. As an accredited provider, AASLD must collect information from all planners, faculty and others involved in the planning and control of continuing medical education (CME) activities to disclose all financial relationships with ineligible companies during the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the content.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to mitigate conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Anahita Rabiee, MD
Grant/Research Support: Grifols

Coskun O Demirtas, MD
Nothing to Disclose

Augusto Villanueva, MD, PhD
Scientific Consultant/Advisor: Genentech, MedPace

Neehar Parikh, MD, MS
Scientific Consultant/Advisor: Eli Lilly, Genentech, Bristol Myers-Squibb, Exact Sciences, Bayer, Sirtex, AstraZeneca, Exelixis, FujiFilm Medical
Grant/Research Support: Exelixis, Bayer, Target Pharmasolutions, Exact Sciences, Genentech

Manon Allaire, MD
Scientific Consultant/Advisor: AstraZeneca, Abbott, Roche
Speakers Bureau: AstraZeneca, Bayer, AbbVie, Gilead, Roche, Sirtex

Reviewers and Staff:

Nikroo Hashemi, MD, MPH
Nothing to Disclose

Renumathy Dhanasekaran, MD, PhD
Grant/Research Suppport: NIIH, American College of Gastroenterology

Sally Cook, CMP, CHCP
Nothing to Disclose

Powered By